GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Long-Term Debt

AVBP (ArriVent BioPharma) Long-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Long-Term Debt?

ArriVent BioPharma's Long-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.


ArriVent BioPharma Long-Term Debt Historical Data

The historical data trend for ArriVent BioPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Long-Term Debt Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Long-Term Debt
- - - -

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

ArriVent BioPharma  (NAS:AVBP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


ArriVent BioPharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.